Morton Brown Family Wealth’s Taysha Gene Therapies TSHA Stock Holding History

Morton Brown Family Wealth’s Portfolio TSHA Stock Details TSHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-260	Closed	-$850	–	306
2025 Q3	$850	Hold	260	–	–	﹤0.01%	249
2025 Q2	$601	Hold	260	–	–	﹤0.01%	293
2025 Q1	$361	Hold	260	–	–	﹤0.01%	301
2024 Q4	$450	Hold	260	–	–	﹤0.01%	263
2024 Q3	$523	Hold	260	–	–	﹤0.01%	250
2024 Q2	$588	Hold	260	–	–	﹤0.01%	207
2024 Q1	$746	Hold	260	–	–	﹤0.01%	201
2023 Q4	$460	Buy	+260	New	+$518	﹤0.01%	270

Other funds holding TSHA

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Morton Brown Family Wealth's TSHA Position: Q4 2025 in Review

Morton Brown Family Wealth sold out of Taysha Gene Therapies (TSHA) in Q4 2025, closing a stake of 260 shares — an estimated $850 sold.

Morton Brown Family Wealth first reported a position in TSHA in Q4 2023 and held it in 8 quarters. The position peaked at $850 in Q3 2025. 195 funds tracked by Wall St. Rank hold TSHA as of Q4 2025.

Morton Brown Family Wealth reported no remaining Taysha Gene Therapies position as of Q4 2025 after selling out during the quarter.
Morton Brown Family Wealth sold 260 Taysha Gene Therapies shares in Q4 2025, an estimated $850.
Morton Brown Family Wealth first reported a position in Taysha Gene Therapies in Q4 2023 and held it in 8 quarters.
Morton Brown Family Wealth's Taysha Gene Therapies position peaked at $850 in Q3 2025.
195 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q4 2025.

Based on Morton Brown Family Wealth's 13F filing for Q4 2025, filed 28 Jan 2026.